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Objectives: To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on
ancestral envelope sequences.
Methods: HIV-2/simian immunodeficiency virus (SIV) ancestral transmembrane
protein sequences were reconstructed and ancestral peptides were derived from the
helical region 2 (HR2). The activity of one ancestral peptide (named P3) was examined
against a panel of HIV-1 and HIV-2 primary isolates in TZM-bl cells and peripheral
blood mononuclear cells and compared to T-20. Peptide secondary structure was
analyzed by circular dichroism. Resistant viruses were selected and resistance
mutations were identified by sequencing the env gene.
Results: P3 has 34 residues and overlaps the N-terminal pocket-binding region and
heptad repeat core of HR2. In contrast to T-20, P3 forms a typical a-helical structure in
solution, binds strongly to the transmembrane protein, and potently inhibits both HIV-2
(mean IC50, 63.8 nmol/l) and HIV-1 (11 nmol/l) infection, including T-20-resistant
isolates. The N43K mutation in the HR1 region of HIV-1 leads to 120-fold resistance
to P3 indicating that the HR1 region in transmembrane glycoprotein is the target of P3.
NoHIV-2-resistant mutations could be selected by P3 suggesting that the genetic barrier
to resistance is higher in HIV-2 than in HIV-1. HIV-1-infected patients presented
significantly lower P3-specific antibody reactivity compared to T-20.
Conclusion: P3 is an HIV-2/SIV ancestral peptide with low antigenicity, high stability,
and potent activity against both HIV-1, including variants resistant to T-20, and HIV-2.
Similar evolutionary biology strategies should be explored to enhance the production of
antiviral peptide drugs, microbicides, and vaccines.
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Introduction
Over the last decade, the inhibition of viral entry has
become one of themost attractive fields in the research for
new anti-HIV-1 molecules. Currently, there are two
entry inhibitors approved for antiretroviral therapy, the
fusion inhibitor peptide enfuvirtide (or T-20; Fuzeon;
Roche AQ1) [1] and the CCR5 antagonist maraviroc
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(Selzentry; Pfizer) [2]. T-20 is a linear peptide composed
of 36 amino acids that mimics the sequence of
gp41 helical region 2 (HR2) of the HIV-1 LAI isolate
[3,4]. T-20 inhibits HIV-1 entry by competitive binding
to the complementary helical region 1 (HR1), thereby
blocking the formation of the six-helix bundle structure
and preventing viral fusion [5–7]. Despite strong anti-
HIV-1 activity, the genetic barrier for T-20 resistance is
low [7,8] and resistance mutations are usually found
within the 36-45 positions of HR1 region [7,9]. T-20 has
poor bioavailability and has to be injected subcutaneously
twice daily, complicating patient adherence to treatment.
Currently, T-20 is only used as a salvage therapy in HIV-1
infection [10–12]. Novel fusion inhibitor peptides
have been developed in an attempt to improve antiviral
potency, increase in-vivo stability, and overcome T-20
resistance [7,13]. T-1249 is a representative second
generation 39-mer peptide derived from HR2 consensus
sequences [14,15]. It is a strong inhibitor of HIV-1 but the
elevated production costs and drug formulation difficul-
ties associated with its long size, have hampered its clinical
development beyond phase I/II trials [16]. Sifuvirtide
is a third generation fusion inhibitor peptide that has
shown promising results in phase II clinical studies being
active against a broad range of HIV-1 isolates, including
T-20-resistant strains [7,13,17].
HIV type 2 (HIV-2), the second causative agent of AIDS,
is responsible for localized epidemics mainly in west
Africa and in few other countries (e.g., Portugal and
France), affecting an estimated 1–2 million patients
worldwide [18]. HIV-2 is composed of eight groups
termed A–H of which group A is by far the most
disseminated worldwide [19–21]. HIV-1 and HIV-2 have
different evolutionary histories [22] and share only 50% of
genetic similarity [23]. Consequently, some anti-HIV-1
drugs have limited or no activity on HIV-2, namely
nonnucleoside reverse transcriptase inhibitors, some
protease inhibitors, and T-20 [4,24,25]. T-20 has no
activity on HIV-2 possibly because its sequence
divergence from HIV-2 prevents it from binding to the
HR1 target in gp36 envelope glycoprotein [24,26,27].
The aim of the current work was to produce new HR2-
based peptides to inhibit HIV-2 fusion and entry.
To enhance the likelihood of inhibiting replication of
all HIV-2 strains, the candidate peptides were derived
from ancestral HIV-2 and SIVmn gp36 sequences. We
found that one selected peptide, named P3, potently
inhibited the fusion and entry of both HIV-1 and HIV-2.
Materials and methods
Virus stocks and titration
A total of 26 primary isolates were included in this
study (seven HIV-1 and 19 HIV-2); all isolates were
characterized for coreceptor usage as described previously
[27]. HIV reference strains were obtained by transfection
of HEK293T cells with pNL4-3 (HIV-1), pSG3.1
(HIV-1), or pROD10 (HIV-2) plasmids using Fugene 6
reagent (Roche, Switzerland) according to manufacturer’s
instructions. Pseudoviruses carrying the vesicular stoma-
titis virus (VSV) envelope were produced by cotransfec-
tion of HEK293T cells with pSG3.1Denv plasmid and a
plasmid expressing VSVenvelope (pHEF-VSVG). HIV-1
variants resistant to T-20 were propagated in CEM-SS
AQ2cells according to a protocol available at www.aidsrea-
gent.org. The 50% tissue culture infectious dose (TCID50)
of all viruses was determined in a single-round viral
infectivity assay using a luciferase reporter gene assay in
TZM-bl cells [27].
Peptide design
Custom peptides were derived from ancestral gp36 HR2
sequences reconstructed from a phylogenetic tree of HIV-
2 and simian immunodeficiency virus (SIV) reference
sequences (see Support Digital Content 1, http://links.
lww.com/QAD/A306 for a list of reference sequences
used). Reconstruction of ancestral character states was
performed by maximum likelihood in PAUP version 4
software [28]. MODELTEST [29] estimated best-fit
models of molecular evolution for maximum likelihood
analyses. The chosen model was GTRþGþI [30].
Tree searches were also performed in PAUP version
4.0 using the nearest-neighbor interchange (NNI) and
tree bisection and reconnection (TBR) heuristic search
strategies and bootstrap resampling.
Peptides were produced commercially by Genemed
Synthesis (San Antonio, Texas, USA). They were
modified with the N-terminus acetylated and the C-
terminus as a carboxamide, the salt form being acetate.
Reverse-phase high-pressure liquid chromatography
(HPLC) was used for purification (>95%) and mass
spectrometry for confirmation analysis.
Circular dichroism spectroscopy
Circular dichroism spectra were recorded for P3 and T-20
in 10mmol/l phosphate buffer and 100mmol/l NaF
(pH 7.4) using a Jasco 810 spectropolarimeter equipped
with a temperature control unit Julabo F25. Spectra were
recorded at 258C in the far ultraviolet (UV) region (185–
240 nm), using a 0.1 cm pathlength cell (Helma UL, Lda AQ3),
with a 50 nm/s scan speed, an 8-s response time, and 2 nm
bandwidth. For each spectrum, four scans were averaged.
P3 and T-20 concentration was previously determined by
absorbance at 280 nm using an extinction coefficient
of e280¼ 13940M
ÿ1 cmÿ1 and e280¼ 18350M
ÿ1 cmÿ1,
respectively, in a UV-Visible spectrophotometer Jasco V-
530. The final concentration used for P3 and T-20 was of
104 and 47mmol/l, respectively. For protein secondary
structure estimation, circular dichroism spectra were
deconvoluted using the CDSSTR [31] deconvolution
algorithm on Dichroweb [32,33]. Circular dichroism
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spectra of the appropriate buffers were recorded and
subtracted from the protein spectra.
Peptide-binding assay
ELISA was developed to study the binding specificity
of peptide P3 to its predicted target in HIV-2 env gp36.
Polystyrene immune module microwells (Maxisorp;
NuncAQ4 , Roskilde, Denmark)were coatedwith each peptide
at a concentration of 50mg/ml in phosphate buffered saline
(PBS) solution and incubated overnight at 48C. After two
washes with PBS, microwells were blocked with 5% of
bovine serumalbumin (BSA; SigmaAQ5 -Aldrich,USA) inPBS
for 2 h at 378Candwashed twicewith PBS.A recombinant
gp36 protein with a polyhistidine tag (rgp36) previously
produced in our laboratory [34] was diluted in PBS
containing 0.05% of Tween-20 (Bio-Rad, USA) (PBS-T)
and added (100ml) at a concentration of 2.5mg/ml and
incubated for 1 h at 378C. After five washes with PBS-T, a
1 : 2000 dilution of mouse monoclonal antipolyhistidine
antibody conjugated to alkaline phosphatase (Sigma-
Aldrich) in PBS-T was added (100ml) and incubated
for 1 h at 378C. After another five washes with PBS-T,
p-nitrophenyl phosphate tablets (Sigma-Aldrich) were
added as a chromogenic substrate, and the optical density
was measured in a Tecan MP-500 plate reader (Tecan,
Ma¨nnedorf, Switzerland) at 405 nm against a reference
wavelength of 620nm. The cut-off value of the assay,
calculated as the mean optical density value of negative
controls þ two times the standard deviation (SD), was
determined for each peptide using wells in which the
peptide was incubated with PBS instead of rgp36. The
results of the assay are expressed quantitatively as optical
densitypeptide/optical densitycut-off ratios (optical density/
cut-off ratio).
Drug susceptibility assays
The antiviral activity of fusion inhibitors was evaluated
using a single-round viral infectivity assay and a viral
replication inhibition assay. The former was performed
using the TZM-bl reporter cells as previously described
[27]. Briefly, cells were infected with 200 TCID50 of each
virus. Infections were performed in the presence of serial-
fold dilutions of inhibitors in growth medium, supple-
mented with DEAE-dextran. After 48h of infection,
luciferase expression was quantified with the One-Glow
luciferase assay substrate reagent (Promega, USA) according
to manufacturer’s instructions. The cytotoxicity of the
compoundswas evaluated using control wells in the absence
of the virus. Additional cell viability studies were also
performed in peripheral bloodmononuclear cells (PBMCs)
incubated in the presence of up to 20mmol/l of peptide and
evaluated with alamarBlue reagent (Invitrogen, USA).
For the viral replication inhibition assay, phytohemag-
glutinin-stimulated PBMCs were infected at a multi-
plicity of infection of 0.01 in the presence of serial-fold
dilutions of inhibitors in growth medium, followed by
incubation for 7–11 days. Viral replication was measured
by a p24 assay (INNOTEST HIV Antigen mAb; Inno-
genetics, Ghent, Belgium).
At least two independent experiments were performed for
each analysis and each assay was set up in duplicate wells.
Dose–response curve parameters were estimated using
the sigmoidal dose–response (variable slope) equation
in Prism version 4.0c for Macintosh (GrahPad Software,
San Diego, California USA, www.graphpad.com).
Time-of-addition experiments
Time-of-addition experiments were set in single-round
viral infectivity assays to measure the antiviral activity of
P3 against HIV-1 (strain SG3.1) and HIV-2 (strain ROD)
at different time-points. T-20 and AMD3100 were used
as controls for inhibiting different stages of viral entry.
TZM-bl cells were infected with 200 TCID50 of
HIV-1SG3.1 in the presence of P3 (129 nmol/l), T-20
(1 nmol/l), or AMD3100 (58 nmol/l) or with 200
TCID50 of HIV-2ROD in the presence of_ P3
(876 nmol/l) or AMD3100 (32 nmol/l). These concen-
trations correspond to two-fold the IC90 value of each
drug [27]. The peptide was added at various times either
before or after infection. In the former, the peptide was
added both to cells and viruses in separate. When added
to cells only, an additional washing step with PBS
(twice with 200ml) was performed before proceeding to
infection. Luciferase expression was quantified after 48 h
of infection as mentioned above.
Antigenic reactivity assay
A new ELISA assay was developed to measure antigenic
reactivity of peptides in HIV-infected patients using
an ELISA protocol similar to the one described for the
binding assay. Briefly, microwells were independently
coated with each peptide at a concentration of 10ml/ml
in PBS solution and incubated overnight at 48C. After
blocking with BSA, 100ml of a 1 : 300 dilution of plasma
samples collected from 29 HIV-2 and 30 HIV-1-infected
patients (all naive to T-20) in PBS-T was added and
incubated for 1 h at 378C. Wells were then washed six
times with PBS containing 0.1% of Tween 20 and a
1 : 2000 dilution of goat antihuman immunoglobulin G
(Fc specific) conjugated to alkaline phosphatase (Sigma-
Aldrich) in PBS-Twas added. Following incubation, the
color was developed and optical densities were measured
as described above. The clinical cut-off value of the assay,
calculated as the mean optical density value of HIV-
seronegative samplesþ two times the SD, was determined
using samples from healthy HIV-seronegative individuals
(n¼ 10). The results of the assay are expressed quanti-
tatively as optical densityclinical sample/optical densitycut-off
ratios (optical density/cut-off ratio).
Selection of P3 resistance mutations
Primary HIV-1 and HIV-2 strains were used for selection
of resistance mutations to P3 in PBMCs, using a
standardized procedure as described elsewhere [35].
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Phytohemagglutinin-stimulated PBMCs were infected at
a multiplicity of infection of 0.01 and selections started
with concentrations below the IC50 level. Viral replica-
tion was monitored weekly by p24 antigen assay. Culture
supernatants were harvested for subsequent genotypic
analysis by sequencing. To this end, RNA was extracted
using QIAmp viral RNA Mini Kit (Qiagen, Germany),
according to manufacturer’s instructions, and reverse
transcribed using Titan One Tube RT-PCR System
(Roche, Switzerland). The env gene (positions 6203–
8817 in HIV-1 HXB2 and positions 6673 - 9268 in
HIV-2 BEN) was amplified by nested PCR, with the
Expand Long Template PCR System kit (Roche,
Switzerland) and sequenced. Primers used for amplifica-
tion and sequencing are described in Support Digital
Content 2 and 3, http://links.lww.com/QAD/A306.
Statistical analysis
Statistical analyses were performed using Prism version
4.0c for Macintosh (GrahPad Software) with a level of
significance of 5%.
Results
Design and structure of ancestral peptides
Maximum likelihood methods were used to reconstruct
ancestral transmembrane protein sequences at several
nodes of the envelope gene phylogenies that represent
ancestors to diverse HIV and SIV virus clades (Fig. 1a).
These sequences were aligned (Fig. 1b) and three peptides
were derived covering different functional domains of the
HR2: P1 (36 mer), P2 (42 mer), and P3 (34 mer)
(Fig. 1c). Due to high hydrophobicity, P1 and P2 were
very difficult to synthesize and reconstitute in an
appropriate buffer suitable for cell culture assays. There-
fore, only P3 was analyzed for antiviral activity.
P3 overlaps the N-terminal pocket-binding region and
heptad repeat core of the HR2 region (positions 628–661
of HIV-1 HXB2 Env). It differs by 21 amino acids from
the consensus HIV-1 sequence and by six amino acids
from consensus HIV-2. However, the positions a and d of
the heptad repeat, considered critical for HIV-1HR1/
HR2 binding [36], were quite conserved. There were
only four changes: I635V and Y638L, involving amino
4 AIDS 2013, Vol 00 No 00
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Fig. 1. Sequence and structure of ancestral peptides. (a) Ancestral reconstruction of HIV-2 gp36 sequences; the interior nodes
highlighted by numbered circles in the phylogenetic tree correspond to the ancestral sequence used for peptide design. The scale bar
represents evolutionary distances in substitutions per site. (b) Alignment of the gp41/gp36 HR1-HR2 segment, containing HIV-2,
simian immunodeficiency virus (SIV), and HIV-1 consensus sequences, as well as the ancestral sequences. Points represent
similarity relative to HIV-2 consensus and dashes represent gaps in the alignment. Sequences are numbered according to HIV-1
HXB2, Env position/gp41 position. (c) Alignment of consensus HRAQ8 -2 sequences from HIV-2, SIV, and HIV-1 with T-20, P1, P2, and
P3. Sequences are numbered according to HIV-1 HXB2, Env position/gp41 position. Positions a and d of HR2 represent the residues
involved in HIV-1HR1/HR2 interaction. The pocket-binding domain and lipid-binding domains are highlighted. (d) Circular
dichroism spectra for P3 and T-20 peptides. b-structures include sheets and turns. NRSMD, normalized root mean square deviation.
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acids with hydrophobic side chains, and L645R and
S649A, involving amino acids from different chemical
groups.
T-20 and P3 overlap in 24 amino acids of the heptad
repeat core and diverge in 14 residues (58%). P3 is more
hydrophilic than T-20 (percentage of hydrophilic residues
is of 62% in P3 and 56% in T-20) [37] and its predominant
secondary structure in solution is an a-helix (42%). T-20
has a lower content of regular secondary structure elements
in solutionwith only 19%of helicity, as previously reported
(Fig. 1d) [38].
P3 is a potent inhibitor of HIV-1 and HIV-2
infection
The antiviral activity of peptide P3 was first evaluated in
single-round viral infectivity assays against 20 group A
HIV-2 isolates, of which 19 were primary isolates, and
nine HIV-1 isolates, including seven highly diverse
primary isolates (Support Digital Content 4, http://links.
lww.com/QAD/A306). P3 potently inhibited both
HIV-2 and HIV-1 infection (Table 1). Remarkably, P3
was significantly more active against HIV-1 than against
HIV-2 (IC50 were 63.8 nmol/l for HIV-2 vs. 11 nmol/l
for HIV-1, P< 0.0001). Similar results were obtained
in the viral replication inhibition assay in PBMCs. P3
inhibited HIV-2 and HIV-1 replication in PBMCs at IC50
of 109.3 and 12.1 nmol/l, respectively (P< 0.0001;
Support Digital Content 5, http://links.lww.com/
QAD/A306). No cytotoxicity was observed in vitro
either in TZM-bl culture cells or primary PBMCs at
all concentrations tested (up to 20mmol/l). P3 did not
inhibit the entry of a pseudovirus carrying the vesicular
stomatitis virus envelope glycoprotein (VSV-G) indi-
cating that its antiviral activity is HIV-envelope specific
(Support Digital Content 6, http://links.lww.com/
QAD/A306).
Compared with T-20, P3 was significantly more active
as judged by the IC50 against HIV-2 and significantly
less active against HIV-1 (P< 0.0001 for both cases;
Table 1 and Fig. 2). Nonetheless, P3 and T-20 had
similar IC90 ranges (P3, 6.2–1785.5 nmol/l; T-20, 0.5–
1285.3 nmol/l) and similar dose–response curve slopes
when tested against HIV-1, predicting similar antiviral
activity in vivo [39,40]. Importantly, the antiviral activity
of P3 and T-20 was null after washing cells that were
preexposed to these peptides with PBS (Fig. 3a).
In contrast, AMD3100 remained fully active. P3 lost
almost 30% of its activity when added 3 h after virus
infection but sustained its potent activity even when
added 3 h prior to infection. In all, these results indicate
that P3 is quite stable and that it inhibits viral fusion
by binding to the virus particles and not to the cell.
P3 and T-20 bound strongly to rgp36, a recombinant
HIV-2 transmembrane protein in an ELISA assay (30-fold
above the cut-off for P3; Fig. 3b). This suggested that the
activity of P3, like that of T-20 and other fusion inhibitor
peptides, was mediated through strong binding to
its putative target in the transmembrane glycoprotein
of the envelope complex [41]. To investigate the binding
activity of these peptides to HIV-1, we expressed the
rgp41 polypeptide equivalent to the rgp36 polypeptide.
However, neither P3 nor T-20 bound to rgp41 in the
ELISA assay (data not shown) suggesting that unlike
rgp36, rgp41 does not form the coiled-coil structure to
which T-20 (and most likely P3) bind in the virus particles
[42]. Why rgp41 does not assume this coiled-coil
structure and rgp36 apparently does is unknown at
this time.
The antigenicity of P3 and T-20 peptides was examined
with plasma samples collected from HIV-2-infected and
HIV-1-infected patients, all naive to T-20. The majority
of HIV-2 patients (93%) had P3-specific antibodies,
whereas 45% had T-20-specific antibodies (data not
shown). This was expected as the amino acid sequence of
P3 was derived from an ancestral HIV-2/SIV sequence.
Likewise, the majority of HIV-1 patients (90%) had T-20-
specific antibodies, whereas 67% had P3-specific
antibodies. Of note, the mean binding affinity of the
T-20-specific antibodies from HIV-1 patients was
significantly higher compared to P3-specific antibodies
(Fig. 3c). These results demonstrate that P3 is weakly
antigenic in HIV-1 patients compared to T-20.
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Table 1. Antiviral activity of P3 and T-20 against HIV-1 and HIV-2 primary isolates.
Parametera P3 (nmol/l) T-20 (nmol/l)b P valuec
HIV-1 (n¼9)
IC50 (95% CI) 11 (6.5–18.4) 1.2 (0.7–2.2) <0.0001
IC90 (95% CI) 366.4 (117.5–1145.5) 95.9 (26.3–350.8) 0.107
Hill slope (95% CI) 0.6 (0.4–0.82) 0.5 (0.4–0.6) 0.263
HIV-2 (n¼20)
IC50 (95% CI) 63.8 (51.9–78.5) 281.5 (223.2–354.9) <0.0001
IC90 (95% CI) 709.6 (435.5–1158.8) 3881.5 (2393.3–6280.6) <0.0001
Hill slope (95% CI) 0.9 (0.7–1.1) 0.8 (0.7–1) 0.492
aIC50, IC90, and Hill slope best-fit values were inferred from sigmoidal dose–response (variable slope) curves adjusted to combined results of HIV-1
and HIV-2 isolates, and represent geometric mean values; 95% CI – 95% confidence interval.
bT-20 susceptibilities were obtained for the same HIV-1 and HIV-2 viral panel [27].
cP value for comparison of best-fit values using the F-test.
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P3 inhibits the replication of most T-20-resistant
HIV-1 variants
To determine whether P3 is able to inhibit the infection of
HIV-1 strains resistant to T-20, we measured the suscepti-
bility of HIV-1 variants carrying well defined T-20
resistance mutations to P3 [43,44]. Notably, P3 exhibited
potent activity against all but one T-20-resistant strains (IC50
range, 0.15–11.8 nmol/l; Table 2). The mutation N43K
conferred high-level resistance to both P3 (2140-fold) and
T-20 (2677-fold). Moreover, the V38A/N42D mutations
conferred increased susceptibility to P3 (seven-fold lower
IC50 compared to the wild-type). These results suggest that
P3 could be used as an alternative for the treatment of
patients infected with T-20-resistant HIV-1 strains.
Selection of P3-resistant variants
To investigate the mechanism of action and the pathways
of resistance to P3, resistance mutations were selected
in vitro by repeated passage of HIV-1 and HIV-2 primary
isolates in PBMCs in the presence of either constant or
increasing concentrations of P3, according to the viral
replication capability [35]. For HIV-1, the N43K
substitution in the HR1 region of gp41 was the only
mutation selected in env after 59 days in culture (eight
passages) in the presence of 212 nmol/l of P3. Inhibition
of replication of this mutant virus with P3 occurred at
an IC50 of 1.9mmol/l and IC90 of 13.1mmol/l,
which represent a 120-fold and 56.4-fold decrease in
susceptibility, respectively. Under the same experimental
conditions and despite repeated attempts, we were not
able to select P3-resistant HIV-2 isolates. Collectively,
these results indicate that the HR1 region in the
transmembrane glycoprotein is the target of P3 and
suggest that the pathway of HIV-1 resistance to P3 differs
from that of T-20 and the genetic barrier to P3 resistance
is significantly higher in HIV-2 than in HIV-1.
6 AIDS 2013, Vol 00 No 00
110
(a)
(b) (d)
(c)
100
90
80
70
60
50
40
30
20
10
0
–10 0
0
2500
5000
7500
10000
12500
15000
32000
32250
32500
500
1000
1500
2000
P = 0.107
P < 0.0001
P3
P3
T-20
T-20
1x10–4 1x10–3 1x10–2 1x10–1 1x100 1x101
Peptide concentration (nM)
P3
T-20
%
 in
hi
bi
tio
n 
of
 H
IV
-1
 is
ol
at
es
IC
90
 
(nM
) fo
r H
IV
-1
1x102 1x103 1x104 1x105
110
100
90
80
70
60
50
40
30
20
10
0
–10
1x10–4 1x10–3 1x10–2 1x10–1 1x100 1x101
Peptide concentration (nM)
P3
T-20
%
 in
hi
bi
tio
n 
o
f H
IV
-1
 is
ol
at
es
IC
90
 
(nM
) fo
r H
IV
-2
1x102 1x103 1x104 1x105
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(variable slope) curves using the F-test.
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Fig. 3. Mechanism of action and antibody reactivity of P3. (a) Time-of-addition assays for P3 with HIV-1 and HIV-2. T-20 and
AMD3100 were used as control drugs. In these experiments, each drug was added at different time-points either before (cells and
viruses, separately) or after HIV infection. (b) Binding activity of P3 and T-20 to HIV-2 rgp36 in an ELISA assay. (c) Antibody
reactivity of P3 and T-20 in HIV-1-infected patients. Bars represent mean values. Results from P3 are in open squares and from T-20
are in closed circles. P values were obtained with the Mann–Whitney U-test.
Table 2. Comparison of antiviral activity of P3 and T-20 on T-20-resistant HIV-1 variants.
P3 T-20
HIV-1 variant
Susceptibility
to T-20a
IC50 nmol/l
(95% CI)
Fold-
increaseb
IC50 nmol/l
(95% CI)
Fold-
increaseb P valuec
NL4-3 D36G (parental) S 0.4 (0.2–1.2) 1 0.03 (0.01–0.06) 1 0.0002
NL4-3 (D36G) V38A R 1.5 (0.5–5.1) 3.8 43.8 (21.8–87.8) 1460 <0.0001
NL4-3 (D36G) V38A/N42D R 0.06 (0.01–0.3) 0.15 118.2 (63.0–221.7) 3940 <0.0001
NL4-3 (D36G) V38A/N42T R 4.7 (1.9–11.5) 11.8 482.0 (324.1–716.8) 16 066.7 <0.0001
NL4-3 (D36G) N42T/N43K R 855.9 (628.0–1167.0) 2139.8 80.3 (61.1–105.6) 2676.7 <0.0001
CI, confidence interval.
aSensitive (S) or Resistant (R).
bFold-increase of IC50 concentration relative to NL4-3 D36G (parental).
cP value for comparison of best-fit values between P3 and T-20, using the F-test.AQ9
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Discussion
We show here that an ancestral peptide (named P3)
derived from the HR2 domains of HIV-2 and SIV
transmembrane glycoproteins potently inhibits both
HIV-1 and HIV-2 cell entry and replication. The
rationale for using ancestral sequences of the trans-
membrane envelope glycoprotein as a source for the
new antiviral peptide was to minimize HIV sequence
divergence by tracing the most likely evolutionary
path along the phylogeny and capture more conserved
structural features of the HR2 sequences [45,46]. The
potent activity of P3 against divergent HIV-1 and HIV-2
primary isolates demonstrates that our strategy was highly
successful. The potent activity of P3 on HIV-1 was not
expected but it might be due to the conservation in P3 of
the residues located in critical positions involved in the
HR1/HR2 interaction (a and d residues) [36] and/or to
the presence of an alanine at position 22 (corresponding
to position 138 in gp41). An alanine at this position
increases the binding affinity of HR2 region to HR1 and
enhances the activity of HR2-based HIV-1 fusion
inhibitor peptides [47].
The N43K mutation in the HR1 region of HIV-1 was
sufficient to confer high-level resistance to this peptide.
These results suggest that, like T-20, P3 acts by selectively
binding to the HR1 region in the transmembrane
glycoprotein of HIV-1. However, P3 potently inhibited
the replication of T-20-resistant viruses bearing the V38A
and/or the N42D resistance mutations indicating that
the pathway of HIV-1 resistance to P3 differs from that
of T-20. We were not able to generate HIV-2 isolates
resistant to P3 even after 60 days in culture suggesting
that the genetic barrier for resistance to P3 might be
significantly higher in HIV-2 than in HIV-1.
Peptides with high helical content like P3 tend to be
more stable and less susceptible to proteolytic degradation
in biological fluids than unstructured peptides like
T-20 [7,13]. In addition, they usually display high anti-
HIV-1 potency due to an increased binding affinity for
HR1 [48,49]. Indeed, we showed that the potent anti-
HIV-1 activity of P3 was conserved for at least 3 h.
Moreover, P3 bound strongly to a recombinant HIV
transmembrane protein. Hence, the high helical content
may also contribute to the potent antiviral activity of P3.
Antibodies present in the plasma of HIV-1-infected
patients reacted poorly with P3 as compared to T-20.
This was expected as HIV-1 andHIV-2 differ significantly
in the HR2 region and antibodies naturally generated
against this region in HIV-1 patients were unlikely to
bind to a peptide derived from HIV-2/SIV. As drug-
specific antibodies can compromise the clinical efficacy of
therapeutic proteins either by preventing their exposure
to the active site or by decreasing their half-life [50], the
weaker antigenicity of P3 in HIV-1-infected patients
might translate into a better bioavailability profile and
durable clinical efficacy of P3 in HIV-1-infected patients.
Conclusion AQ6
In summary, we successfully derived an ancestral peptide
(P3) with low antigenicity, high stability, and potent
activity against both HIV-1, including variants resistant to
T-20, and HIV-2. Our findings provide proof of principle
that potent antiviral peptides can be constructed using
evolutionary biology strategies. Such strategies should be
explored to enhance the production of antiviral peptide
drugs, microbicides, and vaccines.
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